CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Lineage Cell Therapeutics, Inc. - LCTX CFD

    1.16
    5.69%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Lineage Cell Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.23
    Open* 1.23
    1-Year Change* 6.03%
    Day's Range* 1.16 - 1.24
    52 wk Range 1.02-1.58
    Average Volume (10 days) 310.50K
    Average Volume (3 months) 15.99M
    Market Cap 241.48M
    P/E Ratio -100.00K
    Shares Outstanding 174.99M
    Revenue 10.52M
    EPS -0.13
    Dividend (Yield %) N/A
    Beta 1.66
    Next Earnings Date Nov 8, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 21, 2023 1.23 -0.03 -2.38% 1.26 1.27 1.23
    Sep 20, 2023 1.26 0.00 0.00% 1.26 1.28 1.26
    Sep 19, 2023 1.28 0.01 0.79% 1.27 1.31 1.27
    Sep 18, 2023 1.29 -0.01 -0.77% 1.30 1.32 1.28
    Sep 15, 2023 1.30 0.03 2.36% 1.27 1.33 1.26
    Sep 14, 2023 1.28 0.01 0.79% 1.27 1.30 1.26
    Sep 13, 2023 1.28 -0.01 -0.78% 1.29 1.31 1.28
    Sep 12, 2023 1.30 0.01 0.78% 1.29 1.32 1.28
    Sep 11, 2023 1.29 0.01 0.78% 1.28 1.34 1.28
    Sep 8, 2023 1.33 0.00 0.00% 1.33 1.37 1.33
    Sep 7, 2023 1.35 0.04 3.05% 1.31 1.36 1.31
    Sep 6, 2023 1.33 -0.03 -2.21% 1.36 1.36 1.32
    Sep 5, 2023 1.34 0.02 1.52% 1.32 1.38 1.31
    Sep 1, 2023 1.32 0.00 0.00% 1.32 1.34 1.30
    Aug 31, 2023 1.29 -0.04 -3.01% 1.33 1.35 1.29
    Aug 30, 2023 1.32 -0.01 -0.75% 1.33 1.39 1.32
    Aug 29, 2023 1.35 0.04 3.05% 1.31 1.37 1.30
    Aug 28, 2023 1.33 0.01 0.76% 1.32 1.35 1.32
    Aug 25, 2023 1.32 -0.02 -1.49% 1.34 1.34 1.30
    Aug 24, 2023 1.32 0.00 0.00% 1.32 1.37 1.30

    Lineage Cell Therapeutics, Inc. Events

    Time (UTC) Country Event
    Wednesday, November 8, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Lineage Cell Therapeutics Inc Earnings Release
    Q3 2023 Lineage Cell Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, March 7, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Lineage Cell Therapeutics Inc Earnings Release
    Q4 2023 Lineage Cell Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 14.703 4.341 1.826 3.515 4.988
    Revenue 14.703 4.341 1.826 3.515 4.988
    Cost of Revenue, Total 0.728 1.426 0.385 0.412 0.302
    Gross Profit 13.975 2.915 1.441 3.103 4.686
    Total Operating Expense 37.223 53.029 28.273 42.391 -31.728
    Selling/General/Admin. Expenses, Total 22.508 18.212 15.571 24.031 24.726
    Research & Development 13.887 33.714 11.117 15.948 18.755
    Unusual Expense (Income) 0 -0.523 0 -77.711
    Operating Income -22.52 -48.688 -26.447 -38.876 36.716
    Interest Income (Expense), Net Non-Operating -1.365 3.727 1.817 16.499 -82.531
    Other, Net -1.927 1.691 2.706 3.143 -1.315
    Net Income Before Taxes -25.812 -43.27 -21.924 -19.234 -47.13
    Net Income After Taxes -26.353 -43.27 -20.685 -11.827 -46.784
    Minority Interest 0.08 0.251 0.036 0.118 0.794
    Net Income Before Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
    Net Income -26.273 -43.019 -20.649 -11.709 -45.99
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
    Income Available to Common Incl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
    Dilution Adjustment
    Diluted Net Income -26.273 -43.019 -20.649 -11.709 -45.99
    Diluted Weighted Average Shares 169.792 164.502 150.044 145.533 126.903
    Diluted EPS Excluding Extraordinary Items -0.15474 -0.26151 -0.13762 -0.08046 -0.3624
    Diluted Normalized EPS -0.15474 -0.26469 -0.13762 -0.08046 -0.75823
    Depreciation / Amortization 0.1 0.2 1.2 2 2.2
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 3.225 2.386 1.915 2.998 4.553
    Revenue 3.225 2.386 1.915 2.998 4.553
    Cost of Revenue, Total 0.127 0.119 0.102 0.235 0.215
    Gross Profit 3.098 2.267 1.813 2.763 4.338
    Total Operating Expense 8.249 9.028 8.554 8.249 8.787
    Selling/General/Admin. Expenses, Total 4.249 4.724 4.348 4.422 5.27
    Research & Development 3.873 4.185 4.104 3.592 3.302
    Depreciation / Amortization
    Operating Income -5.024 -6.642 -6.639 -5.251 -4.234
    Interest Income (Expense), Net Non-Operating 0.232 0.45 -0.123 0.151 -0.658
    Other, Net -0.411 -0.015 0.4 -0.475 -1.89
    Net Income Before Taxes -5.203 -6.207 -6.362 -5.575 -6.782
    Net Income After Taxes -5.203 -4.404 -6.362 -6.116 -6.782
    Minority Interest -0.026 0.032 0.008 0.047 0.019
    Net Income Before Extra. Items -5.229 -4.372 -6.354 -6.069 -6.763
    Net Income -5.229 -4.372 -6.354 -6.069 -6.763
    Income Available to Common Excl. Extra. Items -5.229 -4.372 -6.354 -6.069 -6.763
    Income Available to Common Incl. Extra. Items -5.229 -4.372 -6.354 -6.069 -6.763
    Diluted Net Income -5.229 -4.372 -6.354 -6.069 -6.763
    Diluted Weighted Average Shares 170.592 170.127 170.002 169.786 169.731
    Diluted EPS Excluding Extraordinary Items -0.03065 -0.0257 -0.03738 -0.03574 -0.03985
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.03065 -0.0257 -0.03738 -0.03574 -0.03985
    Unusual Expense (Income) 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 60 111.549 43.999 57.519 36.358
    Cash and Short Term Investments 57.875 58.358 41.562 30.716 30.741
    Cash & Equivalents 11.355 55.742 32.585 9.497 23.587
    Short Term Investments 46.52 2.616 8.977 21.219 7.154
    Total Receivables, Net 0.297 50.84 0.004 23.94 3.719
    Accounts Receivable - Trade, Net 0.297 50.84 0.004 0.044 0.891
    Prepaid Expenses 1.828 2.351 2.433 2.863 1.898
    Total Assets 123.664 174.545 107.949 125.478 101.66
    Property/Plant/Equipment, Total - Net 5.673 4.872 5.63 8.175 5.835
    Property/Plant/Equipment, Total - Gross 11.523 10.174 9.945 12.766 9.02
    Accumulated Depreciation, Total -5.85 -5.302 -4.315 -4.591 -3.185
    Intangibles, Net 46.692 46.822 47.032 48.248 3.125
    Long Term Investments 0 33.733
    Other Long Term Assets, Total 0.627 0.63 0.616 0.864 0.505
    Total Current Liabilities 18.981 47.116 7.769 6.494 6.812
    Accounts Payable 2.393 3.543 2.611 2.427 2.359
    Accrued Expenses 7.131 25.049 4.416 3.985 4.332
    Notes Payable/Short Term Debt 0 0 0.523 0 0
    Current Port. of LT Debt/Capital Leases 0.036 0.03 0.016 0.033 0.07
    Other Current Liabilities, Total 9.421 18.494 0.203 0.049 0.051
    Total Liabilities 50.325 82.324 11.75 12.519 7.82
    Total Long Term Debt 0.084 0.03 0.026 0.077 1.958
    Long Term Debt 0
    Capital Lease Obligations 0.084 0.03 0.026 0.077 1.958
    Minority Interest -1.403 -1.323 -1.072 -1.712 -1.594
    Other Liabilities, Total 30.587 34.425 2.951 4.345 0.644
    Total Equity 73.339 92.221 96.199 112.959 93.84
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 440.28 434.529 393.944 387.062 354.27
    Retained Earnings (Accumulated Deficit) -363.37 -337.097 -294.078 -273.422 -261.856
    Treasury Stock - Common
    Other Equity, Total -3.571 -5.211 -3.667 -0.681 1.426
    Total Liabilities & Shareholders’ Equity 123.664 174.545 107.949 125.478 101.66
    Total Common Shares Outstanding 170.093 169.477 153.096 149.804 127.136
    Note Receivable - Long Term 0 22.104
    Goodwill, Net 10.672 10.672 10.672 10.672
    Deferred Income Tax 2.076 2.076 2.076 3.315
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 49.655 60 68.509 74.026 81.872
    Cash and Short Term Investments 46.814 57.875 66.355 72.03 79.944
    Cash & Equivalents 15.451 11.355 24.752 70.857 78.062
    Short Term Investments 31.363 46.52 41.603 1.173 1.882
    Total Receivables, Net 0.203 0.297 0.434 0.707 0.515
    Accounts Receivable - Trade, Net 0.203 0.297 0.434 0.707 0.515
    Prepaid Expenses 2.638 1.828 1.72 1.289 1.413
    Total Assets 113.205 123.664 131.148 135.922 144.52
    Property/Plant/Equipment, Total - Net 5.584 5.673 4.652 3.869 4.548
    Property/Plant/Equipment, Total - Gross 11.694 11.523 10.464 9.414 10.135
    Accumulated Depreciation, Total -6.11 -5.85 -5.812 -5.545 -5.587
    Goodwill, Net 10.672 10.672 10.672 10.672 10.672
    Intangibles, Net 46.659 46.692 46.724 46.757 46.789
    Other Long Term Assets, Total 0.635 0.627 0.591 0.598 0.639
    Total Current Liabilities 17.225 18.981 22.739 25.091 24.593
    Accounts Payable 3.001 2.393 2.865 2.589 2.956
    Accrued Expenses 3.126 7.131 7.46 6.678 6.642
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.051 0.036 0.025 0.029 0.031
    Other Current Liabilities, Total 11.047 9.421 12.389 15.795 14.964
    Total Liabilities 42.755 50.325 52.2 53.075 57.973
    Total Long Term Debt 0.133 0.084 0.016 0.019 0.026
    Capital Lease Obligations 0.133 0.084 0.016 0.019 0.026
    Deferred Income Tax 0.273 2.076 2.076 2.076 2.076
    Minority Interest -1.435 -1.403 -1.395 -1.348 -1.329
    Other Liabilities, Total 26.559 30.587 28.764 27.237 32.607
    Total Equity 70.45 73.339 78.948 82.847 86.547
    Common Stock 441.299 440.28 439.148 437.151 435.818
    Retained Earnings (Accumulated Deficit) -367.742 -363.37 -357.016 -350.947 -344.184
    Other Equity, Total -3.107 -3.571 -3.184 -3.357 -5.087
    Total Liabilities & Shareholders’ Equity 113.205 123.664 131.148 135.922 144.52
    Total Common Shares Outstanding 170.174 170.093 169.886 169.748 169.727
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -26.273 -43.019 -20.649 -11.709 -45.99
    Cash From Operating Activities 1.059 -23.561 -19.753 -31.947 -30.882
    Cash From Operating Activities 0.582 0.663 0.895 1.131 1.081
    Amortization 0.145 0.21 1.216 1.998 2.192
    Deferred Taxes
    Non-Cash Items 7.901 -2.511 -2.516 -21.464 11.197
    Cash Interest Paid 0.013 0.013 0.02 0.028 0.155
    Changes in Working Capital 18.704 21.096 1.301 -1.903 0.638
    Cash From Investing Activities -46.159 9.745 13.038 16.957 11.816
    Capital Expenditures -0.413 -0.354 -0.064 -0.44 -3.287
    Other Investing Cash Flow Items, Total -45.746 10.099 13.102 17.397 15.103
    Cash From Financing Activities 1.632 36.93 29.865 0.617 5.774
    Financing Cash Flow Items -0.123 -1.155 -0.383 0.654 0.161
    Issuance (Retirement) of Stock, Net 1.787 38.105 5.127 0.063 5.962
    Issuance (Retirement) of Debt, Net -0.032 -0.02 25.121 -0.1 -0.349
    Foreign Exchange Effects -0.873 -0.02 -0.063 0.07 0.006
    Net Change in Cash -44.341 23.094 23.087 -14.303 -13.286
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -4.372 -26.273 -19.919 -13.85 -7.087
    Cash From Operating Activities -11.242 1.059 9.362 14.842 21.904
    Cash From Operating Activities 0.138 0.582 0.441 0.296 0.15
    Amortization 0.033 0.145 0.113 0.065 0.032
    Non-Cash Items 1.098 7.901 7.168 5.861 1.685
    Cash Interest Paid 0.002 0.013 0.013 0.009 0.005
    Changes in Working Capital -8.139 18.704 21.559 22.47 27.124
    Cash From Investing Activities 15.426 -46.159 -41.057 -0.143 -0.046
    Capital Expenditures -0.188 -0.413 -0.429 -0.143 -0.046
    Other Investing Cash Flow Items, Total 15.614 -45.746 -40.628 0 0
    Cash From Financing Activities 0.001 1.632 1.51 0.546 0.513
    Financing Cash Flow Items -0.037 -0.123 -0.112 -0.074 -0.008
    Issuance (Retirement) of Stock, Net 0.051 1.787 1.645 0.635 0.529
    Foreign Exchange Effects -0.1 -0.873 -0.795 -0.161 -0.042
    Net Change in Cash 4.085 -44.341 -30.98 15.084 22.329
    Deferred Taxes 0 0
    Issuance (Retirement) of Debt, Net -0.013 -0.032 -0.023 -0.015 -0.008
    Cash Taxes Paid 1.803

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Lineage Cell Therapeutics, Inc. Company profile

    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company''s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
    Industry: Biotechnology & Medical Research (NEC)

    2173 Salk Ave Ste 200
    CARLSBAD
    CALIFORNIA 92008-7354
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    Oil - Crude

    90.14 Price
    +0.710% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    US100

    14,710.90 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    BTC/USD

    26,580.90 Price
    -0.220% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    ETH/USD

    1,594.24 Price
    +0.230% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading